Report #2851282

Received Jul 25, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: May 1, 2025
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	LA

Symptoms (2)

ErythemaSwelling

Symptom narrative

Redness; Swelling; This non-serious case was reported by a physician via sales rep and described the occurrence of erythema in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 01-MAY-2025, the patient received the 1st dose of Shingrix (left deltoid). On an unknown date, an unknown time after receiving Shingrix, the patient experienced erythema (Verbatim: Redness) and swelling (Verbatim: Swelling). On 16-JUL-2025, the outcome of the erythema and swelling were resolved. The reporter considered the erythema and swelling to be related to Shingrix. The company considered the erythema and swelling to be related to Shingrix. Additional Information: GSK receipt date: 16-JUL-2025 The patient experienced redness and swelling.